Sagimet Biosciences Inc
SGMT8.450USD
+0.200+2.42%
收盤 08/04, 16:00（美東）報價延遲15分鐘
272.05M總市值
虧損本益比TTM
關於 Sagimet Biosciences Inc 公司
Sagimet Biosciences Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發一種稱爲脂肪酸合酶 (FASN) 抑制劑的治療藥物，該藥物針對因脂肪酸棕櫚酸酯過量生產而導致的疾病中功能失調的代謝途徑。該公司的主要候選藥物 denifanstat 是一種口服、每日一次的藥丸，也是正在開發的用於治療代謝功能障礙相關脂肪性肝炎 (MASH) 的選擇性 FASN 抑制劑。除了 MASH，該公司還在評估 denifanstat 在痤瘡和特定形式的癌症中的作用，在這些疾病領域中，脂肪酸代謝失調也起着關鍵作用。Denifanstat 正在進行中度至重度尋常痤瘡的 III 期臨牀試驗，以及與貝伐單抗聯合治療複發性多形性膠質母細胞瘤 (GBM) 的 III 期試驗。
公司簡介
公司代碼SGMT
公司名稱Sagimet Biosciences Inc
上市日期Jul 14, 2023
CEOMr. David Happel
員工數量14
證券類型Ordinary Share
年結日Jul 14
公司地址155 Bovet Rd., Suite 303
城市SAN MATEO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94402
電話16505618600
網址https://sagimet.com/
公司代碼SGMT
上市日期Jul 14, 2023
CEOMr. David Happel
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Mr. Paul W. Hoelscher
Mr. Paul W. Hoelscher
Independent Director
Independent Director
--
--
Mr. Thierry Chauche
Mr. Thierry Chauche
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Elizabeth Grammer, Esq.
Ms. Elizabeth Grammer, Esq.
Independent Director
Independent Director
--
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
183.73K
-5.54%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
持股股東
持股股東
佔比
KPCB PBD Associates LLC
6.19%
Point72 Asset Management, L.P.
5.72%
AP11 Limited
4.91%
Blue Owl Capital Holdings LP
4.33%
Alyeska Investment Group, L.P.
3.89%
Other
74.96%
股東類型
持股股東
佔比
Hedge Fund
19.57%
Investment Advisor
14.64%
Corporation
11.58%
Investment Advisor/Hedge Fund
7.50%
Research Firm
2.27%
Individual Investor
1.46%
Pension Fund
0.60%
Bank and Trust
0.10%
Private Equity
0.04%
Other
42.26%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
201
18.06M
58.88%
-8.71M
2025Q1
199
18.50M
63.07%
-6.39M
2024Q4
183
22.20M
72.39%
-4.47M
2024Q3
166
24.34M
79.36%
-2.24M
2024Q2
157
25.83M
85.10%
-301.40K
2024Q1
134
27.23M
89.77%
+13.80M
2023Q4
94
18.02M
81.13%
+2.10M
2023Q3
73
15.74M
73.17%
+13.03M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
KPCB PBD Associates LLC
1.90M
6.19%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.76M
5.72%
-561.43K
-24.24%
Mar 31, 2025
AP11 Limited
1.50M
4.91%
-150.06K
-9.07%
Jun 24, 2025
Blue Owl Capital Holdings LP
1.33M
4.33%
+4.47K
+0.34%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.19M
3.89%
-98.07K
-7.60%
Mar 31, 2025
The Vanguard Group, Inc.
1.15M
3.76%
+22.73K
+2.01%
Mar 31, 2025
Baker Bros. Advisors LP
953.00K
3.11%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
787.81K
2.57%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
724.80K
2.36%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
724.77K
2.36%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.04%
Avantis US Small Cap Equity ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
